Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
3D Printers for Specialists - 210 Asian Countries Perfect for Solo Female Travelers
- 3I'm a woman who's into weightlifting. Was I man enough for the creatine-packed 'Man Cereal'?
- 4Relish the World: Notable Caf\u00e9s You Really want to Attempt
- 5What loving-kindness meditation is and how to practice it in the new year
- At UN climate conference, some activists and scientists want more talk on reforming agriculture
- 5 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows
- Watching ‘Home Alone’ with the kids this holiday season? Brace yourself for '6-7.'
- Innospace's rocket crashes in first commercial launch in Brazil; shares tumble
- True serenity: Investigating Emotional well-being and the Advantages of Contemplation
- Remain Cool and Solid: Top Summer Food sources for 2024
- A photographer's journey to capture a blood moon rising over the South China Sea. 'It was an incredible moment'
- Exemplary Fragrances: A Manual for Notorious Scents
- 6 Pet Sitting Administrations for Your Cherished Pets
